Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Completed
Bayer
Phase 4
2009-12-01
Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with
skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related
to acne vulgaris. However, it has not been clinically tested for this purpose. The current
study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris
and PIH.
Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH)
Completed
Derm Research, PLLC
Phase 4
2009-12-01
Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with
skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related
to acne vulgaris. However, it has not been clinically tested for this purpose. The current
study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris
and PIH.
Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin
Completed
Galderma Laboratories, L.P.
Phase 4
2010-06-01
The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1%
to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product
labeling for three weeks.
Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin
Completed
Galderma Laboratories, L.P.
Phase 4
2010-06-01
The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in
subjects with healthy skin applied according to product labeling for three weeks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.